Payment overview · 2025
General Payments
$135.11
6 reported records · 5 companies
Healthcare provider profile · identity verified
Ann Wilt, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · HANOVER, PA · NPI 1356890123
Verified facts
What the public records show
CMS Open Payments records show Ann Wilt, CRNP received $135.11 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 41.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Lumigan by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.54 | 41.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.25 | 19.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.90 | 14.7% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $17.10 | 12.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.32 | 11.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $135.11 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $34.98 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $26.25 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.56 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 681 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 436 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 429 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 366 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 362 | 42 |
| Potassium Chloride | Potassium Chloride | 303 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 286 | 37 |
| Lorazepam | Lorazepam | 275 | 71 |
| Tramadol Hcl | Tramadol Hcl | 272 | 60 |
| Gabapentin | Gabapentin | 271 | 31 |
| Eliquis | Apixaban | 258 | 45 |
| Omeprazole | Omeprazole | 249 | 35 |
| Sertraline Hcl | Sertraline Hcl | 234 | 32 |
| Lisinopril | Lisinopril | 180 | 31 |
| Donepezil Hcl | Donepezil Hcl | 179 | 29 |
| Losartan Potassium | Losartan Potassium | 176 | 19 |
| Trazodone Hcl | Trazodone Hcl | 175 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 153 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 19 |
| Mirtazapine | Mirtazapine | 128 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 127 | 36 |
| Metformin Hcl | Metformin Hcl | 126 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 15 |
| Pregabalin | Pregabalin | 114 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 111 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 14 |
| Memantine Hcl | Memantine Hcl | 109 | 11 |
| Simvastatin | Simvastatin | 104 | 15 |
| Baclofen | Baclofen | 103 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 90 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 90 | suppressed |
| Carvedilol | Carvedilol | 88 | 13 |
| Myrbetriq | Mirabegron | 86 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 85 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 79 | 22 |
| Spironolactone | Spironolactone | 79 | 15 |
| Bumetanide | Bumetanide | 73 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | suppressed |
| Famotidine | Famotidine | 70 | 15 |
| Clonazepam | Clonazepam | 69 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 69 | 35 |
| Doxazosin Mesylate | Doxazosin Mesylate | 68 | suppressed |
| Alprazolam | Alprazolam | 67 | 12 |
| Divalproex Sodium | Divalproex Sodium | 65 | 14 |
| Lansoprazole | Lansoprazole | 64 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 61 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 59 | suppressed |
| Tradjenta | Linagliptin | 56 | suppressed |
| Trulicity | Dulaglutide | 55 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 52 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 52 | suppressed |
| Prednisone | Prednisone | 52 | 27 |
| Buspirone Hcl | Buspirone Hcl | 50 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 49 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | suppressed |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 45 | 23 |
| Olanzapine | Olanzapine | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Latanoprost | Latanoprost | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Fentanyl | Fentanyl | 38 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Lorazepam Intensol | Lorazepam | 36 | 14 |
| Lovastatin | Lovastatin | 36 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Digoxin | Digoxin | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 18 |
| Gemtesa | Vibegron | 35 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 22 |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | suppressed |
| Lumigan | Bimatoprost | 31 | suppressed |
| Timolol Maleate | Timolol Maleate | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Nystatin | Nystatin | 29 | 16 |
| Atropine Sulfate | Atropine Sulfate | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Invokana | Canagliflozin | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Ingrezza | Valbenazine Tosylate | 26 | suppressed |
| Phenobarbital | Phenobarbital | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 24 | suppressed |
| Nystop | Nystatin | 24 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 11 |
| Acetic Acid | Acetic Acid | 22 | suppressed |
| Allopurinol | Allopurinol | 22 | suppressed |
| Anastrozole | Anastrozole | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 19 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 21 | 21 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 20 | suppressed |
| Lacosamide | Lacosamide | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 14 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 13 |
| Lagevrio (Eua) | Molnupiravir | 17 | 17 |
| Leflunomide | Leflunomide | 17 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | 11 |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Xcopri | Cenobamate | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Loteprednol Etabonate | Loteprednol Etabonate | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Glipizide Er | Glipizide | 11 | suppressed |
| Perphenazine | Perphenazine | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $135.11 · 6 records | ABBVIE INC. | AMPYRA, BOTOX, Fluad, Flucelvax, INBRIJA, QULIPTA, SHINGRIX, VOQUEZNA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error